Disminución de la Listeriosis Neonatal como beneficio colateral de la profilaxis del Streptococo del Grupo B en el embarazo.

Disminución de la Listeriosis Neonatal como beneficio colateral de la profilaxis del Streptococo del Grupo B en el embarazo.

There was an error loading this content. Please refresh the page to try again, or contact us if you continue to experience problems.



We tested the hypothesis that declines in Listeria monocytogenes in infants are related to declines in rates of early-onset Group B Streptococcus (GBS) infections associated with widespread prophylaxis using agents with Listeria activity.


We performed a retrospective cohort analysis using a national administrative database Pediatric Health Information System (PHIS). We searched for ICD-9 codes for Listeriosis in infants <30 days old and for early-onset GBS infection of any kind in infants <5 days old during the study period.


We identified 183 cases of Listeriosis in infants <30 days in the PHIS database from 1992 to 2013. We noted a statistically significant decline in case rates over the years studied: 4.78 cases per 10,000 admissions (1992–1995) to 2.24 (1996–2002) to 1.31 from (2003–2013) ( p < 0.0001). Case rates of early-onset GBS dropped significantly over the study period: 30.10 cases per 1000 admissions (1992–1995) to 21.70 (1996–2002) to 18.57 (2003–2013) ( p < 0.0001). There was a statistically significant correlation between yearly rates of Listeriosis and early-onset GBS (rho: 0.53; p = 0.01).


These results support the hypothesis of a “collateral benefit” to widespread GBS prophylaxis and further support the position that empiric antibiotic regimens for febrile infants may no longer require Listeria activity.

Reductions in neonatal listeriosis: “Collateral benefit” of Group B streptococcal prophylaxis

Journal of Infection, 2016-03-01, Volume 72, Issue 3, Pages 317-323, Copyright © 2016 The British Infection Association